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Introduction
Induction of multifollicular growth in IVF treatment, or ovarian stimulation, is essential for success, as IVF efficacy correlates with the number of fertilized oocytes obtained (Sunkara et al., 2011) . Historically, IVF procedures have used protocols involving administration of gonadotrophins to increase the number of oocytes available for fertilization and eventual embryo transfer.
Original gonadotrophin preparations, available in pre-IVF times, were defined by their FSH and LH bioactivity, as they were licensed before precise gonadotrophin assays existed (Lunenfeld, 1963; Lunenfeld and Donini, 1966) . This explains that the later preparations, i.e., highly purified HMG and FSH preparations, are by analogy still defined by FSH and LH bioactivity rather than content. For HMG preparations, achieving equipotent LH bioactivity has progressively become problematic because urines of ageing menopausal women are markedly richer in FSH than LH. Hence, other sources of LH activity became necessary. An existing highly purified HMG preparation, Menopur® (Ferring Pharmaceuticals, St Prex Switzerland) , uses HCG of pituitary origin as source of LH bioactivity. Menopur serves as reference preparation in the present study. Conversely, a different new HMG preparation, Meriofert®, studied here uses HCG extracted from urine of pregnant patients as source of LH activity. One justification of the present study, therefore, is to compare HMG preparations having different sources of HCG, from pituitary and trophoblastic origin, as source of LH bioactivity.
Ovarian stimulation regimens for IVF generally achieve pituitary desensitization (down-regulation) with a gonadotrophin-releasing hormone (GnRH) analogue to prevent premature luteinization. Pituitary downregulation with GnRH agonist is an effective way of recruiting an adequate number of pre-ovulatory follicles for IVF (Hughes et al., 1992) .
Meriofert (IBSA Institut Biochimique SA) is a highly purified menotrophin preparation containing 75 IU (or 150 IU) FSH and LH activity per vial. Unlike other HMG preparations, which contain FSH and LH/HCG from pituitary origin both extracted from urine of menopausal women, Meriofert combines highly purified FSH extracted from the urine of menopausal women and LH activity that is primarily provided by highly purified HCG of chorionic origin extracted from the urine of pregnant women.
A previous study comparing Meriofert with Menopur in ovarian stimulation for IVF (Alviggi et al., 2013) , showed that Meriofert was equivalent to Menopur in clinical efficacy based on the total number of oocytes retrieved (primary end-point). In that study, Meriofert was more efficient (fewer units of gonadotrophin for a same number of oocytes and higher 17-beta oestradiol levels), compared with Menopur.
These results, however, raised concerns about the possibility of an increased risk of ovarian hyperstimulation syndrome (OHSS) when using Meriofert, thereby, justifying the new study reported here.
The aims of the present study were, therefore, to confirm the noninferiority of Meriofert compared with Menopur with regard to clinical outcome (the primary end point being the total number of oocytes retrieved); to compare the incidence of clinically significant OHSS according to Golan Criteria (Golan and Weissman, 2009 ) between patients treated with Meriofert or Menopur.
Materials and methods

Patients and study design
This prospective, investigator-blind, randomized, controlled, parallelgroup, multicentre, two-arm, non-inferiority study was conducted at six fertility clinics in Denmark (two sites), France (one site), Hungary (one site), Switzerland (one site) and UK (one site). The primary outcome was defined as the total number of oocytes retrieved. The trial was assessor blinded, and all investigators, central assessors, laboratory personnel and sponsor staff involved in analysing and interpreting data were kept blinded to the treatment allocation throughout the trial. Blinding was ensured by providing patients with sealed and anonymous boxes with the study drug and avoiding any contact between assessors and study drug. Drug dispensing and accountability was carried out by dedicated personnel, such as appointed pharmacists or study nurses.
Patients with infertility, planning to undergo IVF, with or without intracytoplasmic sperm injection, who achieved successful downregulation (defined as endometrial thickness <7 mm or serum oestradiol level ≤50 pg/ml) with a standard GnRH-agonist long protocol regimen were selected for possible study inclusion between March 2011 and April 2013. Pregnancy outcome data were collected in the subsequent 9 months, whereas frozen embryo transfer data were collected during the following 2 years.
The eligibility criteria were female age between 18 and 39 years, body mass index (BMI) 30 kg/m 2 or less, less than three prior completed ART cycles, baseline (day 2-3) FSH less than 10 IU/L and oestradiol less than 80 pg/ml, and a normal uterine cavity as demonstrated on recent hysteroscopy, sonohysterogram or hysterosalpingogram. Significant exclusion criteria included primary ovarian failure or poor responders (defined as having fewer than three oocytes retrieved in a previous cycled or with a pre-ovulatory oestradiol serum concentration of <500 pg/ml), polycystic ovarian syndrome, one or both ovaries inaccessible for oocyte retrieval, ovarian cysts greater than 10 mm, stage III or IV endometriosis, untreated hydrosalpinx, untreated thyroid disease, adrenal disease, severe impairment of renal and or hepatic dysfunction and neoplasias. All patients who were screened but excluded met one of these exclusion criteria.
The trial was carried out in accordance with the declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, and local regulatory requirements. The trial protocol was approved by both the local regulatory authorities and the independent ethics committees covering all participating centres (Paris-France: Comité de protection des personnes CPP Before starting HMG administration (Meriofert, IBSA Institut Biochimique SA or Menopur, Ferring Pharmaceuticals), patients underwent standard down-regulation protocol to prevent endogenous gonadotrophin production using a commercially available GnRHagonist (Suprefact®-Sanofi Aventis, Buserelin, 0.2 mg/day or Decapeptyl®-Ipsen, Triptorelin, 3.75 mg/day). Down-regulation was started in the mid-luteal phase of the previous cycle, i.e., day 21 of the cycle preceding the stimulation cycle. Concomitant treatment with the oral contraceptive pill was allowed, but not mandatory.
Patients were evaluated using transvaginal ultrasound and oestradiol measurements to determine down-regulation status. Patients were considered to be down-regulated if the endometrial thickness was les than 7 mm or serum oestradiol was 50 pg/ml or less (185 pmol/l), and either no cysts were present on ultrasound or, if present, were less than 10 mm diameter.
After confirmation of down-regulation, patients were randomized to one of the two treatment groups, and were instructed on selfadministration and supplied with the assigned medication, with the first dose set at 150 IU for patients aged 35 years or less, or 225 IU for patients aged greater than 35 years and commenced 0-3 days after confirmation of down-regulation. Administration of GnRH-agonist was continued until HCG administration. Ovarian response to stimulation was assessed by transvaginal ultrasound scans and oestradiol serum measurements.
Tolerance to HMG preparations was evaluated by inspection of injection sites and, in the case of pain, asking patients to assess postinjection severity and duration.
Transvaginal ultrasound was carried out using a high-resolution transvaginal probe. Measurements of all follicles 10 mm or wider in diameter were made using two perpendicular diameters, including the greatest diameter visualized. The mean of these two measurements were recorded for each follicle and plotted on a folliculogram. Oestradiol was measured with a commercially available immunoassay kit at each study site (Siemens Automatic Immunoassay System, Paris, France; Beckman Coulter's Access 2 Immunoassay System, Aldridge, UK; Abbott Axsym System, Budapest, Hungary; AutoDelfia Oestradiol assay, Odense, Denmark; Oestradiol II Cobas 6000, Copenhagen, Denmark; Elecsys Estradiol Roche Diagnostic, Basel, Switzerland).
Daily gonadotrophin administration was continued until at least two follicles had a mean diameter greater than 16 mm, serum oestradiol levels greater than 400 pg/ml (or 1500 pmol/l), or both. Starting on treatment day 5-7, the HMG dosage was adjusted according to ovarian response, but coasting was not permitted.
Final luteinization and oocyte maturation were achieved through injection of 10,000 IU of commercially available human derived HCG (Gonasi-HP ® IBSA Italia; Choriomon ® , IBSA Institut Biochimique SA; or Pregnyl®, MSD). A lower HCG dosage was allowed only in cases with an increased risk of OHSS (peak oestradiol on the day of HCG >3500 pg/ml).
Oocytes and partner/donor sperm were collected 34-36 h after HCG administration. Oocytes were fertilized in vitro (IVF) with or without intracytoplasmic sperm injection.
Progesterone administration began on the day of oocyte retrieval and continued as per centres' normal IVF treatment standard procedures (but not less than 14 days after embryo transfer , Merck Serono) 90 mg once a day. All the cleaved embryos obtained were evaluated on culture day 2, irrespective of the planned transfer day. Evaluation consisted of the assessment of blastomere number, degree of fragmentation (Grade A: ≤ 10%; Grade B: > 10 to ≤25%; Grade C: > 25 to ≤50%; Grade D: > 50%) and cell division aspect (typical or non-typical). For statistical analysis purposes, embryo scoring was categorized into four quality classes: top-, good-, moderate-and poor-quality embryos.
Transfer of either cleavage stage embryos or blastocyst was permitted. The number of embryos transferred was at the discretion of the investigator in consultation with the patient and with reference to national legislation. Supernumerary embryos were cryopreserved by slow-freezing procedure in all centres but Basel where vitrification of oocytes in the pronucleate stage was performed, according to Swiss legislation. Two weeks after oocyte retrieval, serum HCG levels were measured, even if bleeding had occurred.
In an attempt to obtain data that accurately reflect the actual incidence and severity of OHSS in an IVF protocol, and to insure that this information was captured at each centre under generally comparable conditions, OHSS was characterized for each patient at the time of embryo transfer (early onset) and at the time of serum pregnancy test (late onset) using a standard OHSS evaluation form based on updated Golan criteria (Golan and Weissman, 2009) .
Ongoing pregnancy rate was defined as a pregnancy showing ultrasound embryonic heart activity at 10-11 weeks after embryo transfer. Pregnant patients were given a special form for collecting information on pregnancy outcome and the newborn' s health status for completion by the patient's gynaecologist or obstetrician. Throughout the study, women recorded all adverse events and concomitant medications in a diary.
As new guidelines on biological products require the analysis of the immunogenic potential of therapeutic proteins, in two selected centres (Basel and Budapest), serum samples for anti-FSH, anti-HCG and anti-LH antibodies detection were collected. Patients who did not get pregnant during the first cycle of treatment in the main protocol, and had no previous gonadotrophin exposure before entering the study, were encouraged to undergo a second treatment cycle, to be performed in the same clinic under the supervision of the same investigator. For this second cycle, only Meriofert, and not Menopur, was provided to these patients irrespective of which drug had been used for the first cycle in order to preserve the blindness of the index trial. Serum samples were drawn at baseline, i.e., before starting any treatment, on the day of oocyte retrieval and on the day of beta-HCG pregnancy test. Samples were stored at −20°C and shipped to a centralized laboratory (Kymos Pharma Services SL, Barcelona). All serum samples were analysed by a specific and fully validated electrochemiluminescence screening assays for the presence of anti-FSH, anti-HCG and anti-LH antibodies, following a multitiered approach. Positive samples in the screening assay were analysed by the corresponding confirmatory assay. Positive samples on the confirmatory assay were titrated to determine the amount of antibodies present in the sample.
Statistical analysis
The intention-to-treat population (ITT), i.e., all patients receiving at least one dose of test product, was the primary population for the efficacy analyses. Analyses were also carried out on the per protocol population, i.e., all the patients who underwent oocyte retrieval, excluding major protocol deviators), as well as the population who became pregnant.
The total number of oocytes retrieved 34-36 h after HCG administration, i.e., the primary end-point of the study, was used to test noninferiority of Meriofert versus Menopur. Least-squares means and their associated SE were used to calculate the 95% confidence interval of the difference between the two groups. If the lower bound of the 95% confidence interval of the difference between means (Meriofert minus comparator) was greater than −2.1, then Meriofert was considered to be non-inferior to the comparator.
A multivariate analysis of variance was used to calculate the 95% confidence interval for the difference between treatment groups using investigational centre, women's age and body mass index as covariates. The primary efficacy analysis, including the main effects (treatment and investigational centre), was repeated with the addition of a treatment group by centre interaction term.
For secondary continuous variables, statistical analyses were carried out using analysis of variance (ANOVA) models with factor for treatment group (Meriofert versus Menopur). For ordered categorical variables, the effect of treatment group was analysed using the Cochran-Mantel-Haenszel test, whereas, for non-ordered categorical variables the Fisher's exact test was used. P < 0.05 was considered statistically significant.
Incidence of adverse events was compared using Fisher's exact test for comparison of Meriofert versus Menopur. SAS software (SAS Institute Inc., UK was used for all statistical calculations. The sample size was calculated taking into account previous published papers of studies conducted with the reference product (Platteau et al., 2008) . The sample size was calculated using the Schuirmann's two onesided test, considering the total number of oocytes retrieved, according to non-inferiority experimental design criteria and choosing a twosided alpha (0.05), a power of 80%, a clinically significant difference of 2.1 (20% of 10.5), a standard deviation of 5.9. According to this calculation, a minimum of 250 patients were required to demonstrate non-inferioritym, i.e., 125 patients per group. Taking into consideration the randomization blocks and some possible drop outs, a total of 270 patients were enrolled.
Eligible participants were randomized in blocks of four at each site using a randomization list that was generated with Statistical Analysis Software. Randomization numbers were assigned chronologically. The investigators were asked to keep a record of the names of the patients and their corresponding randomization numbers, thereby allowing easy identification of data in a patient's file if required. The randomization code for each patient was provided to the investigators in individual sealed envelopes for emergency use only, i.e., in case of onset of a serious adverse event that required unblinding of the treatment.
Results
Patients' demographics
A total of 270 patients undergoing IVF were randomized to two groups: Meriofert (n = 135) or Menopur (n = 135). The ITT population included all the 270 patients, of whom 259 proceeded to oocyte retrieval and 240 to embryo transfer (Figure 1) . Ovarian stimulation was interrupted for six patients in the Meriofert group (three owing to poor response and three for risk of OHSS) and five patients in the Menopur group (one for a protocol violation, one for poor ovarian response, two for risk of OHSS and one for investigator decision). Embryo transfer was not carried out for 10 patients randomized to Meriofert (seven with failed fertilization, one for no progressing embryos and two for risk of OHSS), and for nine patients randomized to Menopur (four for failed fertilization, two for no progressing embryos, two for risk of OHSS and one for poor embryo quality).
Among the participants who started an IVF cycle, i.e., ITT population, 95.6% (n = 129/135) in the Meriofert group and 96.3% (n = 130/ 135) in the Menopur group had oocyte retrieval after ovarian stimulation. Three patients in the Meriofert group had only one ovary accessible for oocyte retrieval. These patients were kept in the ITT analysis, but they were excluded from the per protocol population analysis. One patient in the Menopur group did not meet the exclusion criterion 'primary ovarian failure or women known as poor responders' and began the HMG treatment with a starting dose of 300 IU. She was included in the ITT analysis, but excluded from the per protocol population analysis. As a result, the per protocol population included 126 patients in the Meriofert group and 129 in the Menopur group (Figure 1) .
The two treatment groups were well matched in demography, baseline characteristics, duration of infertility and infertility diagnosis ( Table 1 ). The mean age of patients was about 33 years in each treatment group, and 93.3% (n = 126/135) of patients in each group were white. The patients were generally healthy, with an average BMI of about 24 kg/m 2 in each treatment group. No significant differences were observed between the treatment groups for duration of infertility, infertility diagnosis, basal FSH and oestradiol levels. Prior and concomitant minor pathologies affected a wide range of body systems. In each group, over 55% (n = 78/135 in the Meriofert group and n = 75/135 in the Menopur group) of patients reported at least one prior or concomitant pathology, i.e., hyperprolactinaemia, hypothyroidism, endometriosis, endometrial polyps, ovarian cysts, allergies to antibiotics, metal or pollen. No notable differences in prior or concomitant medication use, i.e., anaestheics -the most frequently reported concomitant medication, were reported between the two treatment groups.
Primary end-point: total number of oocytes
In the ITT population, the mean (±SD) number of oocytes retrieved was significantly higher (P = 0.012) in women stimulated with Meriofert (11.6 ± 6.6) than in those stimulated with Menopur (9.7 ± 5.9) ( Table 2) . The difference (Meriofert-Menopur) in mean number of oocytes retrieved was +1.9, with a 95% CI of the difference equal +0.43 to +3.43, i.e., a 95% CI lower limit greater than the predefined clinically significant difference of −2.1. These results were confirmed in the per protocol population patient analysis, for which the total number of oocytes retrieved was 12.3 ± 6.2 in the Meriofert group and 10.1 ± 5.7 in the Menopur group (95% CI of the difference equal +0.68 to +3.61). The HMG start dose, arbitrarily set according to age, was 150 IU/ day for women aged 35 years or younger and 225 IU or 150 IU, depending on expected response, for women aged over 35 years ( Table 3) . As seen, no difference was found in HMG start dose between the two HMG preparation groups. For both HMG preparations, more oocytes were retrieved in the younger age group receiving the lower HMG dose. In each HMG dose group, more oocytes were retrieved in women who received the HMG preparation, which obtained its LH effects from HCG of chorionic origin. Multiple regression analysis demonstrated that the clinic where the treatment took place and BMI, but not patient age, were significantly correlated with the number of oocytes retrieved (P = 0.009 and P = 0.025, for centre and BMI respectively).
Secondary end-points
No statistically significant differences between Meriofert and Menopur were seen for implantation rate (Table 4 ) and pregnancy outcome parameters, including positive serum pregnancy test rate, ongoing pregnancy rate, delivery and live birth rate. Of the women who started stimulation (ITT population), 33% (n = 45/135) in the Meriofert group and 37% (n = 50/135) in the Menopur group achieved an ongoing Protocol violation (n = 1); poor ovarian response (n = 1); OHSS risk (n = 2); continuation of the treatment not in the best interest of the patient (n = 1). c failed fertilization (n = 7); risk of OHSS (n = 2); no progressing embryos (n = 1). d failed fertilization (n = 4); risk of OHSS (n = 2); no progressing embryos (n = 2); poor embryos quality (n = 1). e Only one ovary accessible for oocytes retrieval (n = 3). f Inappropriate enrolment (poor responder patient) (n = 1). (Figure 2A) . The delivery and the live birth rate were the same as all the patients gave birth to at least one living baby. Similar results were reported for the per protocol population ( Figure 2B ). No differences were found in the proportion of women having day 2-3 and 5-6 embryo transfers between the two HMG preparation groups (Table 4) . Although no statistically significant difference were found in the total and mean daily units of HMG used (Table 4) , the duration of the stimulation was shorter in the Meriofert group. The increased number of oocytes and mature (MII) oocytes retrieved in the Meriofert group was also associated with an increased number of cleaved embryos obtained (Table 4) . Embryo quality was equivalent in the two treatment groups (Table 5) . It is of interest that, throughout the stimulation, 17-beta oestradiol levels were statistically higher in the Meriofert group (Figure 3) .
Patients who did not achieve a live birth from their fresh transfer owing to failure of implantation or miscarriage and had supernumerary embryos frozen, or who had all their embryos frozen because of risk of OHSS, were able to undertake a frozen embryo transfer. The statistically significantly higher number of oocytes and cleaved embryos obtained with Meriofert translated into a higher number of cryopreserved embryos available for subsequent transfer. A total of 39 patients in the Meriofert and 28 patients in the Menopur group underwent frozen embryo transfer, resulting in 13 (33.3%) and 6 (21.4%) ongoing clinical pregnancies. The cumulative pregnancy rate was 43% (n = 58/135) with Meriofert and 41.5% (n = 56/135) with Menopur for the ITT population (Figure 2A) , and 46% (n = 58/126) and 43% (n = 56/129), respectively, for the per protocol patient population ( Figure 2B) . One patient had miscarried in the Meriofert group, therefore the live birth rate per frozen transfer resulted to be 30.8% (n = 12/39) in the Meriofert group and 21.4% (n = 6/28) in the Menopur group. No statistically significant difference in the cumulative live birth rate was present (Figure 2A and 2B) .
Safety parameters
Adverse events were reported by 42.2% (n = 57/135) versus 43.7% (n = 59/135) of the study patients, with a similar number of events reported in each group (221 and 208 events in the Meriofert and Menopur groups, respectively). No difference was reported in the frequency of the adverse events with the exception of vascular disorders (hot flushes) that were reported more often in the Meriofert group. The most frequently reported treatment-related adverse events were associated with gastrointestinal disorders (abdominal pain, abdominal distension and nausea) experienced by 20.7% (n = 28/135) of the patients in both treatment groups. These symptoms were deemed to be probably caused by ovarian enlargement and are frequently reported in IVF stimulation regimens. The next most frequently reported adverse events were related to neurological system disorders (predominantly headache and dizziness), which were equally reported in both groups. Fatigue and malaise were also reported in both treatment groups with the same frequency, whereas hot flushes were reported more frequently in the Meriofert group (8.2% versus 1.5%, P = 0.02). No statistically significant difference in the proportion of patients experiencing Serious adverse events was reported between the Meriofert and Menopur groups (5.9% in both treatment groups). Only four events in three patients in the Meriofert group (lower abdominal pain, constipation, ovarian hyperstimulation and ovarian torsion) were considered to be related to the study drug. In the Menopur group, only one case of moderate OHSS was considered to be related to the study drug.
Sympomsn of OHSS were routinely checked on the day of embryo transfer and on the beta-HCG test day; the results are reported in Table 6 . No difference in the frequency and severity of OHSS was detected between the two treatment groups.
Follow-up data showed no difference in term of frequency and type of adverse event occurred during pregnancy between the two treatments. Information was collected for 57 newborns (born to 44 mothers) in the Meriofert group and 60 newborns (born to 49 mothers) in the Menopur group.
Abnormalities at birth were reported for two babies in the Meriofert group (congenital hand malformation with syndactyly for one baby and single umbilical artery for the other) and one in the Menopur group (reporting patent ductus arteriosus, intraventricular haemorrhage neonatal and neonatal respiratory distress syndrome).
Tolerability at the injection site was found to be very good in both treatment groups, with few patients reporting pain (14 patients in the Meriofert group versus 18 in the Menopur group), redness (seven patients versus 14 patients), tenderness (three patients versus eight patients) or itching (one patient versus two patients). In those cases reporting pain, the intensity was mainly mild and limited to the time of injection.
Newborn safety
According to the pregnancy outcome forms collected, 93 deliveries took place: 44 in the Meriofert group and 49 in the Menopur group following fresh embryo tranfer. One patient in each treatment group miscarried after the first trimester. In the Meriofert group, of the 44 deliveries reported, 56.8% (n = 25/44) were caesarean and 43.2% (n = 19/44) vaginal; 18.2% (n = 8/44) were preterm, i.e., before the 37th week of gestation. In the Menopur group, 59.2% (n = 29/49) of deliveries were caesarean and 40.8% (n = 20/49) vaginal; preterm delivery was reported in 18.4% (n = 9/49) patients. Gestational age at delivery was 38.3 ± 2.8 weeks and 38.4 ± 2.6 weeks in the Meriofert and Menopur group, respectively. A total of 117 babies were born, 57 in the Meriofert group and 60 in the Menopur group (Table 7) . A total of 31 (70.5%) and 38 (77.6%) babies respectively were singletons, whereas 26 versus 22 babies were twins. No triplets were reported. A total of 15 (26.3%) and 13 (21.7%) prematurely born babies, i.e., delivery before the 37th gestational week, were reported in the Meriofert and Menopur group, respectively. Among patients with a twin gestation, seven (53.8%) and four (36.4%) had a premature delivery in the Meriofert and Menopur group, respectively. The mean new-born weight was 2.82 ± 0.72 kg and 2.88 ± 0.58 kg in the Meriofert and Menopur group, respectively. Two babies (3.5%) in the Meriofert group and one (1.7%) in the Menopur group reported abnormalities at birth ( Table 7) .
No statistically significant differences were detected in any of the parameters assessed, including the number of abnormalities detected, which was in line with the known frequency for babies born to patients undergoing fertility treatments.
Immunogenicity
A total of 126 samples from 25 patients from the study were analysed to detect antibodies against FSH, LH and HCG. None of the 25 patients analysed had any positive samples for the presence of binding antibodies against FSH and against LH.
Three patients had at least one positive sample for the presence of binding antibodies against HCG, which were considered not clinically relevant as one patient already had a positive result at the beginning of the study (basal) and the remaining two patients had positive results during the study with the last sample returning below the limit, indicating that no patient seroconverted during the study, i.e., no patient was positive at the end of the study. The two positive responses were actually borderline and, as discussed, not confirmed in subsequent analyses in the same patients. Because of the high sensitivity of the assay, those low positive results represented false positive results and were not considered clinically relevant.
Discussion
The use of a new HMG preparation containing highly purified FSH and highly purified HCG of chorionic origin, led to retrieve more oocytes, MII oocytes and cleaved embryos in IVF than an established HMG reference comparator. These data suggest that gonadotrophins of different origin and prepared differently, notably, gaining LH bioactivity from HCG of different origin, can lead to significant differences in ovarian response to ovarian stimulation used in IVF. Interestingly, these differences are encountered despite similar values in the reference bio-efficacy testing.
The results of the present trial showed that the new HMG preparation gaining LH bioactivity from HCG of chorionic origin provided more oocytes, whereas showing a trend for shorter ovarian stimulation duration that required less drug. This, therefore, equates to a higher ovarian yield achieved with the new HMG preparation compared with the reference preparation. Paralleling the above findings, 17-beta oestradiol levels were higher throughout ovarian stimulation in women receiving HMG containing HCG of chorionic origin. These results are concordant and confirm those of a prior study (Alviggi et al., 2013) . Interestingly, the HMG units required to retrieve one single oocyte were not different in the two groups, and the higher 17-beta oestradiol levels did not increase the OHSS incidence. These, in some way, contradictory results should increase awareness about the value of purely statistical results, which should be treated with caution and a more clinically sound approach, especially when secondary endpoints are concerned.
This Phase III trial is the first multicentre, international, single blind, controlled, randomized clinical trial comparing two highly purified HMG preparations gaining their LH bio-activity from HCG of different origin. Although the number of oocytes retrieved and the embryos obtained was different, no statistically significant differences were found between the two treatment groups regarding fertilization and cleavage rates, quality of embryos obtained, implantation, ongoing and cumulative pregnancy rates as well as delivery and live birth rates.
The strength of this study resides in the nature of its design -randomized controlled trial -which anchors the validity of its conclusion: more oocytes retrieved with the new HMG preparation. The fact that this difference also translates into more mature oocytes and embryos being obtained suggests that the new HMG preparation may also foster higher cumulative IVF outcome.
The improved efficacy of cryopreservation favours an increasing preference for elective single embryo transfer to minimize multiple pregnancy risks. This approach values the concept of 'cumulative' pregnancy rates achieved by each ovarian stimulation through both fresh and frozen embryo transfers. In our study, the new HMG preparation and the reference product resulted in an equivalent ongoing and cumulative pregnancy rates (33.3% versus 37.0% for ongoing and 43% and 41.5% for cumulative, respectively). The weakness of the study, however, is that it was not powered for comparing pregnancy rates obtained with the two HMG preparations; therefore, additional studies should be conducted to validate these findings.
Ideally, one would prefer that all in each ovarian stimulation treatment groups received one common and identical HMG dose. Such practice would, however, be ethically unacceptable, as possibly unduly increasing OHSS risks. In our study, HMG start dose was, therefore, set according to age: 150 IU/day in women 35 years or younger, and 150-225 IU/day in women above that age for patient safety reasons. The proportion of women receiving either the 150 IU/ day, or 225 IU/day dose between the two HMG groups was similar (Table 3) . Moreover, in all HMG start-dose groups, more oocytes were retrieved in women receiving HMG gaining LH effects from HCG of chorionic origin.
Our study accommodated the possibility that embryo transfer be carried out on either day 2-3, or day 5-6 to accommodate practices that each group was more familiar with. As shown in Table 4 , there were, however, no differences in proportion of day 2-3 and 5-6 transfers between the two HMG groups.
The aim of ovarian stimulation in IVF is to produce an optimum number of mature oocytes and embryos available for transfer. The choice between the several different formulations of gonadotrophin is between HMG and FSH-only preparations. HMG produced from the urine of menopausal women contains equal FSH and LH bio-activity. This is achieved today by addition of HCG of either pituitary or, trophoblastic origin. FSH-only preparations are composed of either urinary gonadotropins (highly purified FSH) or recombinant FSH, both of which contain no LH activity. More recently, a long acting FSH (corifollitropin alpha) has been developed for which further research is being undertaken for specific subgroups of patients (Pouwer et al., 2012) . The latest Cochrane review (Farquhar et al., 2013) , states that all available gonadotrophin formulations are equally effective and safe for ovarian stimulation in assisted reproduction technique cycles. The choice of product will depend upon the availability, clinician preference, the convenience of its use and the associated costs. The same conclusion is also drawn in the latest National Instituute for Health and Care Excellence guidelines in which cost-effectiveness is specifically mentioned (NICE, 2013) . In conclusion, this study demonstrated that the new HMG preparation gaining LH bioactivity from HCG of chorionic origin is a viable alternative for conducting ovarian stimulation in IVF cycles.
